Trump Imposes 100% Tariffs on Pharma After Price Hikes
Sixteen drugmakers signed deals to lower prices, then raised them anyway. Trump responded with tariffs up to 100 percent and a push to rebuild America's drug supply at home.
Sixteen pharmaceutical companies signed voluntary agreements to lower drug prices with the Trump administration in 2025. All 16 raised list prices on 872 brand-name medications in January 2026, with a median increase of 4 percent. President Trump responded on April 2 with tariffs as high as 100 percent on imported patented drugs.
The price increases came despite those same companies having signed Most-Favored-Nation pricing deals throughout 2025. Pfizer raised prices on 72 products, including a 15 percent hike on its COVID vaccine. Merck increased prices on 18 medications, among them HIV treatment Isentress and insomnia drug Belsomra. White House spokesperson Kush Desai brushed aside concerns, stating "list prices aren't important."
"The discounts addressed in the deals are coming to state Medicaid programs and patients who want to pay cash for some prescriptions," Desai said in January.
For millions of Americans who pay full price at the pharmacy counter, the gap between Washington deal-making and real-world drug costs has never felt wider.
Trump's April 2 proclamation under Section 232 of the Trade Expansion Act imposes a default 100 percent tariff on imported patented pharmaceuticals and their active ingredients. The tiered structure offers 0 percent rates through January 2029 for companies with both MFN deals and domestic manufacturing commitments. Companies with only onshoring plans face 20 percent rates, escalating to 100 percent by April 2030.
"We need to make sure that our drug supply is protected, secure and domestic," a senior administration official told CNBC. "That is what we're doing."
The numbers behind that security argument are stark. The Commerce Department found 53 percent of patented pharmaceuticals distributed domestically are produced outside the United States. Only 15 percent of patented active pharmaceutical ingredients by volume come from domestic sources. The administration framed this import dependence as a national security threat requiring immediate action.
Market analyst Antonio Ciaccia, CEO of 46brooklyn, noted that "the real truth serum is what's happening in the marketplace after those deals occur." Ciaccia stated January price increases aligned with historical patterns despite the MFN agreements.
Tariffs take effect July 31 for companies listed in Annex III of the proclamation, including those without MFN or onshoring deals. All other companies face implementation on Sept. 29. Generic drugs and biosimilars receive a one-year exemption from tariffs.
The administration argues the tariff threat has already spurred approximately $400 billion in new U.S. pharmaceutical manufacturing commitments. Eli Lilly pledged $27 billion to double domestic capacity, while AstraZeneca committed $50 billion to U.S. manufacturing and research. Johnson & Johnson announced a $55 billion investment, including a $2 billion facility in North Carolina.
Not everyone is persuaded. Biotechnology Innovation Organization CEO John Crowley warned tariffs "will raise costs, impede domestic manufacturing, and delay development of new treatments." The American Action Forum called tariffs "a poor instrument for addressing concerns about drug pricing."
Trade deal partners received preferential rates under the new regime. The European Union, Japan, South Korea and Switzerland face 15 percent tariffs. The United Kingdom secured a 10 percent rate under a December 2025 agreement, potentially reducible to zero.
Special exemptions apply to orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, and medical countermeasures for chemical, biological, radiological or nuclear threats. The Commerce Department will establish specific onshoring plan criteria and require periodic compliance reports from participating companies.
Tony Quiñones, CEO of U.S.-based manufacturer Bright Path, applauded the proclamation. "Today's action sends the clearest signal yet that America is serious about manufacturing its own medicines," Quiñones stated.
The enforcement mechanism includes external audits and retroactive tariff reimposition for companies found to have committed fraud in their onshoring or pricing commitments. Trade analysts estimate $274 billion in pharmaceutical and medical product imports in 2025, with 80 percent originating from the five major trade partners now facing preferential rates.
Administration officials emphasized that the tiered structure rewards cooperation while punishing non-compliance. Companies that signed MFN deals but raised prices now face pressure to deliver on promised discounts while accelerating domestic manufacturing investments — a test of whether corporate pledges to Washington translate into relief for the patients waiting at the counter.